首页|亚麻醉剂量艾司氯胺酮对乳腺癌根治术后慢性疼痛的影响

亚麻醉剂量艾司氯胺酮对乳腺癌根治术后慢性疼痛的影响

扫码查看
目的:探讨亚麻醉剂量艾司氯胺酮对乳腺癌根治术患者术后慢性疼痛(CPSP)的影响。方法:招募2021年11月至2022年3月于本院择期行乳腺癌根治术的患者120例,年龄35~64岁,ASA分级Ⅰ-Ⅱ级。随机将患者分为艾司氯胺酮组和舒芬太尼组,每组60例。麻醉诱导开始时,艾司氯胺酮组静注艾司氯胺酮0。3 mg/kg和舒芬太尼0。2 μg/kg,麻醉维持期间艾司氯胺酮的给药速率为0。25 mg·kg-1·h-1,持续吸入七氟烷1%~2%,术毕前30 min停用,术毕即刻给予经静脉患者自控镇痛(patient controlled intravenous analgesia,PCIA)泵,镇痛泵配方为100 mg的艾司氯胺酮+100 μg的舒芬太尼+10 mg的托烷司琼,用生理盐水稀释至100 mL。麻醉诱导开始时,舒芬太尼组静脉注射舒芬太尼0。5 μg/kg,麻醉维持期间瑞芬太尼的给药速率为0。1~0。3µg·kg-1·min-1,术毕前5 min停用,持续吸入七氟烷1%~2%,术毕前30 min停用,PCIA泵配方为150 μg的舒芬太尼+10 mg的托烷司琼,用生理盐水稀释至100 mL。两组PICA泵的参数均为背景剂量2 mL/h,单次给药剂量0。5 mL,锁定时间15 min。主要指标为术后3个月的CPSP发生率,术后3和6个月对患者进行电话随访,记录CPSP有无发生。次要指标为术后48h内疼痛视觉模拟评分(VAS)和Ramsay镇静评分及术后48h内不良事件发生率。术前1d及术后1d、3d时抽取外周静脉血并测定血清中肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6和IL-8浓度。结果:舒芬太尼组失访者2例,艾司氯胺酮组失访者3例。术后3和6个月时,舒芬太尼组分别共有27例(46。6%)和19例(32。8%)患者发生CPSP,其中,轻度疼痛分别有18例(31。0%)和13例(22。4%),艾司氯胺酮组分别有13例(22。8%)和8例(14。0%)患者发生CPSP,其中,轻度疼痛分别有8例(14。0%)和5例(8。8%),艾司氯胺酮组术后3、6 个月CPSP发生率均低于舒芬太尼组(P<0。05)。两组患者术后48h内不同时点VAS评分和Ramsay镇静评分均无统计学差异(P>0。05)。两组间术后2d内镇痛补救率和PCIA泵总按压次数和有效按压次数均无统计学差异(P>0。05)。与舒芬太尼组比较,艾司氯胺酮组术后48h内恶心呕吐发生率降低(P<0。05)。与舒芬太尼组比较,艾司氯胺酮组术后1d和3d时的血清中TNF-α、IL-6和IL-8浓度均下降(P<0。05)。结论:亚麻醉剂量艾司氯胺酮可降低乳腺癌根治术患者CPSP发生率,机制可能与抑制术后炎性反应有关。
Effect of sub-anesthetic dose of esketamine on chronic post-surgery pain in patients undergoing radical mastectomy of breast cancer
AIM:To investigate the effect of sub-anesthetic dose of esketamine on chronic post-sur-gery pain(CPSP)in patients undergoing radical mastectomy of breast cancer.METHODS:A total of 120 patients undergoing elective radical mastecto-my of breast cancer in the operating room of our hospital from November 2021 to March 2022 were enrolled,aged 35-64 years old,and with American Society of Anesthesiologists(ASA)classification Ⅰ to Ⅱ.The subjects were allocated into esketamine group(group E)and sufentanil group(group S),with 60 subjects pergroup,according to a random number table method.At the beginning of anesthe-sia induction,patients in group E were given intra-venous injection of esketamine 0.3 mg/kg and suf-entanil 0.2 μg/kg,and during the maintenance of anesthesia,the administration rate of esketamine was 0.25 mg·kg-1·h-1,sevoflurane was continuously inhaled at 1%to 2%,and stopped 30 minutes be-fore the end of the operation,and a patient-con-trolled intravenous analgesia(PCIA)pump was con-nected immediately after the operation,and esket-amine 100 mg+sufentanil 100 μg+tropisetron 10 mg were added to the analgesia pump,supple-mented with medical 0.9%sodium chloride injec-tion to dilute to 100 mL.At the beginning of anes-thesia induction,patients in group O were intrave-nously injected with sufentanil 0.5 μg/kg,and the administration rate of remifentanil during the anes-thesia maintenance period was 0.1-0.3 μg·kg-1·min-1,and stopped 5 minutes before the end of the operation.Sufentanil 150 μg+tropisetron 10 mg was added to the PCIA pump,supplemented with medical 0.9%sodium chloride injection to dilute to 100 mL.The PICA pump parameters in both groups were set to background dose of 2 mL/h,bolus dose was 0.5 mL,and locked time was 15 min.The main outcome was the incidence of CPSP on postopera-tive 3 months,and the patients were followed up at 3 and 6 months postoperatively to record the oc-currence of CPSP.The secondary outcomes were vi-sual analogue scale of pain(VAS),Ramsay sedation scale and the incidence of postoperative adverse events within 48 hours after surgery.Peripheral ve-nous blood was drawn 1 day before operation and 1 day and 3 days after operation,and the concen-trations of serum inflammatory factors including tu-mor necrosis factor-α(TNF-α),interleukin-6(IL-6)and interleukin-8(IL-8)were measured.RESULTS:There were 2 lost patients in group S and 3 lost pa-tients in group E.At 3 and 6 months after opera-tion,27(46.6%)and 19(32.8%)patients in group S had CPSP,including 18(31.0%)and 13(22.4%)pa-tients with mild pain,respectively.13(22.8%)and 8(14.0%)patients in group E had CPSP,including 8(14.0%)and 5(8.8%)patients with mild pain,re-spectively.The incidence of CPSP in group E was lower than that in group S at 3 and 6 months after operation(P<0.05).The VAS scores and Ramsay se-dation scores of the two groups of patients were similar at different time points after operation with-in48h(P>0.05).The analgesic rescue rate within 2 days after operation,the total number of PCIA pump compressions and the number of effective compressions were not similar between the two groups,and there was no statistical significance(P>0.05).Compared with group S,the incidence of nausea and vomiting in group E was significantly lower within 2 days after operation(P<0.05).The serum levels of TNF-α,IL-6 and IL-8 in the group E were significantly decreased on postoperative 1 and 3 d,compared with group S(P<0.05).CONCLU-SION:Sub-anesthetic dose of esketamine can inhib-it perioperative inflammatory response and lower the incidence of CPSP in patients undergoing breast cancer surgery.

esketaminechronic post-surgery painradical mastectomy of breast cancerinflam-mation

李宁、张会、周俊辉

展开 >

河南省人民医院麻醉与围术期医学科郑州大学人民医院,郑州 450003,河南

河南省胸科医院郑州大学附属胸科医院麻醉科,郑州 450008,河南

艾司氯胺酮 术后慢性疼痛 乳腺癌根治术 炎性反应

河南省医学科技攻关计划联合共建项目河南省科技研发计划联合基金(应用攻关类)

LHGJ20200220232103810054

2024

中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
年,卷(期):2024.29(6)
  • 22